Getting oncolytic virus therapies off the ground.

An international meeting was held on the development and application of replicating viruses for cancer therapy this past March in Banff, Alberta. In this review, using the presentations at this meeting as a backdrop, we discuss how recent scientific and clinical findings are reshaping the development of oncolytic virus therapeutics. Here we identify some of the obstacles that these therapeutics face and discuss evolving strategies, both preclinically and clinically, that are facilitating oncolytic virus development.

[1]  S. Rabkin,et al.  Oncolytic herpes simplex virus vectors for cancer virotherapy , 2002, Cancer Gene Therapy.

[2]  D. Louis,et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses , 1999, Nature Medicine.

[3]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[4]  J. Darnell,et al.  Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport , 1985, Molecular and cellular biology.

[5]  Xiaoliu Zhang,et al.  Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. , 2002, Cancer research.

[6]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[8]  B. Foster,et al.  Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. , 2001, Cancer research.

[9]  J. Nemunaitis,et al.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity , 2001, Gene Therapy.

[10]  O. Wildner,et al.  Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  H. Pehamberger,et al.  A genetically engineered influenza A virus with ras-dependent oncolytic properties. , 2001, Cancer research.

[12]  D. Brough,et al.  TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene , 2002, Cancer Gene Therapy.

[13]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[14]  D. Curiel,et al.  Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. , 2002, Human gene therapy.

[15]  S. Russell,et al.  Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. , 2003, Blood.

[16]  Mani Menon,et al.  Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. , 2002, Cancer research.

[17]  R. Cattaneo,et al.  Efficiency of Measles Virus Entry and Dissemination through Different Receptors , 2002, Journal of Virology.

[18]  Samuel Ce,et al.  Interferon-induced proteins and their mechanisms of action. , 1994 .

[19]  J. Marshall,et al.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Hecht,et al.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Nemunaitis,et al.  Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients , 2003, Cancer Gene Therapy.

[22]  Shaji K. Kumar,et al.  An oncolytic measles virus engineered to enter cells through the CD20 antigen. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  D. Curiel,et al.  Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Fei-Fei Liu.  Novel gene therapy approach for nasopharyngeal carcinoma. , 2002, Seminars in cancer biology.

[25]  A. Fattaey,et al.  Analyses of Single-Amino-Acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein , 2001, Journal of Virology.

[26]  L. Wein,et al.  Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. , 2002, Cancer research.

[27]  Steven A Curley,et al.  Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. , 2002, Cancer research.

[28]  R. Martuza,et al.  Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. Wold,et al.  Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. , 2003, Virology.

[30]  M. Savontaus,et al.  Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells , 2002, Gene Therapy.

[31]  R. Matusik,et al.  Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector , 2002, Journal of Virology.

[32]  O. Colvin,et al.  Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. , 2001, Cancer research.

[33]  E. Wimmer,et al.  Intergeneric poliovirus recombinants for the treatment of malignant glioma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Wold,et al.  Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein , 2000, Journal of Virology.

[35]  D. Heo,et al.  Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. , 2002, Anticancer research.

[36]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[37]  L. Hawkins,et al.  Multigene expression from a replicating adenovirus using native viral promoters. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  C. Bangma.  Targeting of adenoviral vectors for gene therapy of prostate cancer , 2000, Prostate Cancer and Prostatic Diseases.

[39]  F. Goodrum,et al.  p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection , 1998, Journal of Virology.

[40]  S. Brüsselbach,et al.  Combined transductional and transcriptional targeting of melanoma cells by artificial virus‐like particles , 2001, The journal of gene medicine.

[41]  H. Wakimoto,et al.  Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant , 2000, Journal of virology.

[42]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[43]  J. Dawson,et al.  Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein , 2003, Cancer Gene Therapy.

[44]  D. Sze,et al.  Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. , 2003, Journal of vascular and interventional radiology : JVIR.

[45]  H. Wakimoto,et al.  The complement response against an oncolytic virus is species-specific in its activation pathways. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  T. Akhurst,et al.  Tumor-specific transcriptional targeting of suicide gene therapy , 2002, Gene Therapy.